Efficacy of PEG-Loxenatide in Overweight T2DM Patients, 12-Week Multicenter Study

Liye Zhu authored a clinical study on the glucose-lowering efficacy of polyethylene glycol loxenatide (PEG-Loxe) in patients with type 2 diabetes. The dataset likely contains results from a 12-week, multicenter prospective cohort study of 246 patients, using flash glucose monitoring to assess glycemic profiles. It was last updated on 2026-05-19.

Use Cases

• Predicting HbA1c reduction based on baseline patient characteristics like diabetes duration and baseline HbA1c.
• Analyzing correlations between Time in Range (TIR) improvements and demographic/clinical factors.
• Modeling the impact of add-on therapy on cardiometabolic parameters and liver enzymes.
• Comparing pre- and post-treatment glycemic variability metrics such as SDBG, CV, TAR, and TBR.

Strengths

• Includes data from a multicenter prospective cohort study with 246 patients in the final analysis.
• Assesses a comprehensive set of glycemic metrics via flash glucose monitoring, including MBG, TIR, TAR, and TBR.
• Reports specific efficacy outcomes, such as 39.6% of patients achieving HbA1c <6.5% after treatment.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (15.6 KB), indicating limited scope and likely summary-level data.

Provenance

Source

Liye Zhu

Collection Method

Multicenter prospective cohort study with pre-post intervention design, using the Abbott FreeStyle Libre flash glucose monitoring system.

Time Range

Study treatment period was 12 weeks.

Freshness

Last updated 2026-05-19 04:21:03; freshness should be verified.

Geography

The study was conducted on Chinese patients.